The North America Enzymatic Wound Debridement Market would witness market growth of 5.3% CAGR during the forecast period (2023-2030).
Papain and collagenase-based products treat pressure ulcers, diabetic foot, and venous limb ulcers. The main use of collagenase-based enzymatic wound debridement products is the treatment of surgical wounds. Surgical incisions following cancer surgery are frequently substantial and profound, generating exudate that necessitates constant removal. When treated with the right medicines, large wounds are substantially less susceptible to infection. Consequently, the increasing prevalence of chronic illnesses is expected to stimulate market expansion by bolstering the demand for these products.
Researchers are undertaking various initiatives, and key players are developing technologically advanced products owing to the rising demand for these products regionally, which is anticipated to boost market growth. Since awareness about the use of such products is increasing, several technologically advanced products are being introduced in the market. For instance, NexoBrid (NXB), previously referred to as Debriding Gel Dressing (DGD)—derived from the pineapple Bromelain group of enzymes-was introduced in 2017. NXB is an enzymatic wound-debriding drug that can effectively treat deep burn wounds.
North America has a large and aging population, leading to an increased incidence of wounds associated with age-related conditions. The Centers for Disease Control and Prevention report that the number of obesities in the United States rose from 30.5% to 41.9% between 1999–2000 and 2017–March 2020. Concurrently, the majority of chronic obesity increased from 4.7% to 9.2%. Obesity is a major risk factor for conditions such as diabetes, peripheral vascular disease, and venous lack, which can lead to the development of chronic wounds. Diabetic foot ulcers are more prevalent in individuals with obesity. As the obesity rates grow, so does the occurrence of wounds that require specialized care. As a result, these aspects will boost the market growth in the coming years.
The US market dominated the North America Enzymatic Wound Debridement Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $384.9 million by 2030. The Canada market is experiencing a CAGR of 7.7% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 6.8% during (2023 - 2030).
Based on End-use, the market is segmented into Hospitals, Homecare, and Others. Based on Type, the market is segmented into Chronic Wounds (Diabetic Foot Ulcers, Pressure Ulcers, Venous Leg Ulcers, and Others), and Acute Wounds (Burns, and Others). Based on Product, the market is segmented into Collagenase Product, Papain Product, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Enzymatic Wound Debridement Market is Predict to reach $1.3 Billion by 2030, at a CAGR of 6.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ConvaTec Group PLC, Smith & Nephew PLC, Molnlycke Health Care AB, Integra LifeSciences Holdings Corporation, B. Braun Melsungen AG, Coloplast Group, Medline Industries, Inc., 3M Company, HARTMANN Group (Paul Hartmann AG) and MediWound Ltd.
By End-use
By Type
By Product
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
